↓ Skip to main content

An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma.

Overview of attention for article published in Blood Cancer Discovery, October 2023
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 X users
wikipedia
1 Wikipedia page

Readers on

mendeley
15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma.
Published in
Blood Cancer Discovery, October 2023
DOI 10.1158/2643-3230.bcd-23-0176
Pubmed ID
Authors

Ross Firestone, Alexander M Lesokhin, Saad Z Usmani

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 13%
Other 2 13%
Student > Bachelor 1 7%
Professor 1 7%
Unknown 9 60%
Readers by discipline Count As %
Medicine and Dentistry 3 20%
Immunology and Microbiology 2 13%
Biochemistry, Genetics and Molecular Biology 1 7%
Unknown 9 60%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 August 2024.
All research outputs
#6,818,333
of 26,542,140 outputs
Outputs from Blood Cancer Discovery
#150
of 223 outputs
Outputs of similar age
#98,142
of 369,421 outputs
Outputs of similar age from Blood Cancer Discovery
#9
of 16 outputs
Altmetric has tracked 26,542,140 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 223 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 27.9. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 369,421 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.